EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Meibomian Gland-Mediated Drug Delivery via Eyelid Application of Troxipide Nanoparticles Improves an N-Acetylcysteine-Induced Dry Eye

Hiroko Otake, Rie Tanaka, Fumihiko Ogata iD, Manju Misra, Kazutaka Kanai iD, Masanobu Tsubaki, Naoki Yamamoto iD, Naohito Kawasaki iD, Noriaki Nagai iD

Pharmaceutics · 08.08.2026 · 18 (8) · 973

DOI: 10.3390/pharmaceutics18080973 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 08.08.2026. Verfasst von Hiroko Otake und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka 577-8502, Osaka, Japan. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Ministry of Education, Culture, Sports, Science and Technology of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Dry eye disease (DED) is a multifactorial disorder characterized by tear film instability, inflammation, and ocular surface damage, which significantly impairs visual function and quality of life. Conventional ophthalmic formulations, such as eye drops, have low bioavailability owing to rapid elimination, necessitating frequent administration. In this study, we developed an eyelid-applied drug delivery system (DDS) based on troxipide (TRO) nanoparticle formulation (TRO-NP@EG) to achieve sustained ocular surface delivery.

Methods

TRO nanosuspensions were prepared by wet bead milling and incorporated into a Carbopol-based gel. Particle size, dispersion stability, and uniformity were evaluated, and in vitro drug release studies was compared with that of TRO-MP@EG. In vivo drug transfer into tear fluid was assessed in rabbits following eyelid application, and therapeutic efficacy was evaluated in an N-acetylcysteine-induced dry eye model.

Results

TRO nanosuspensions had a mean particle size of approximately 118 nm. TRO-NP@EG exhibited superior dispersion stability and uniformity and achieved 2.5-fold higher drug release than TRO-MP@EG, while the nanoparticles remained in solid form. In vivo studies in rabbits, TRO-NP@EG significantly enhanced drug transfer into tear fluid, primarily via the meibum pathway. Furthermore, TRO-NP@EG significantly improved mucin levels, tear secretion, and tear film stability compared with TRO-MP@EG in an N-acetylcysteine-induced dry eye model.

Conclusions

These findings suggest that eyelid application of nanoparticle-based formulations enables efficient and sustained drug delivery to the ocular surface via the meibomian glands. Therefore, TRO-NP@EG represents a promising therapeutic strategy for DED, providing enhanced efficacy and a novel route of administration for ophthalmic DDSs.

Schlagwörter

Stichwörter der Autor:innen

dry eyeeyelidnanoparticleocular drug deliverytroxipide

Autor:innen und Institutionen

  • Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka 577-8502, Osaka, Japan.
  • Department of Pharmaceutics and Pham. Technology, L. M. College of Pharmacy, Navrangpura, Ahmedabad, GJ 380009, India.
  • Department of Small Animal Internal Medicine II, School of Veterinary Medicine, Kitasato University, 35-1 Higashi 23 ban-cho, Towada 034-8628, Aomori, Japan.
  • Laboratory of Pharmacotherapy, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, 1314-1 Shido, Sanuki 769-2193, Kagawa, Japan.
  • University Startup Promotion Center, Research Promotion Headquarters, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Aichi, Japan.
  • Department of Pharmaceutical Engineering, Faculty of Engineering, Sanyo-Onoda City University, 1-1-1 Daigaku-dori, Sanyo-Onoda 756-0884, Yamaguchi, Japan.

ORCID-Profile: Fumihiko Ogata, Kazutaka Kanai, Naoki Yamamoto, Naohito Kawasaki, Noriaki Nagai

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology
  • Ministry of Education, Culture, Sports, Science and Technology of Japan

Zitieren

APA

Otake, H., Tanaka, R., Ogata, F., Misra, M., Kanai, K., Tsubaki, M., Yamamoto, N., Kawasaki, N., & Nagai, N. (2026). Meibomian Gland-Mediated Drug Delivery via Eyelid Application of Troxipide Nanoparticles Improves an N-Acetylcysteine-Induced Dry Eye. Pharmaceutics, 18(8), 973. https://doi.org/10.3390/pharmaceutics18080973

Vancouver

Otake H, Tanaka R, Ogata F, Misra M, Kanai K, Tsubaki M, et al. Meibomian Gland-Mediated Drug Delivery via Eyelid Application of Troxipide Nanoparticles Improves an N-Acetylcysteine-Induced Dry Eye. Pharmaceutics. 2026;18(8):973. doi:10.3390/pharmaceutics18080973

BibTeX
@article{Otake2026,
  author = {Otake, Hiroko and Tanaka, Rie and Ogata, Fumihiko and Misra, Manju and Kanai, Kazutaka and Tsubaki, Masanobu and Yamamoto, Naoki and Kawasaki, Naohito and Nagai, Noriaki},
  title = {Meibomian Gland-Mediated Drug Delivery via Eyelid Application of Troxipide Nanoparticles Improves an N-Acetylcysteine-Induced Dry Eye},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {973},
  doi = {10.3390/pharmaceutics18080973}
}
Kostenlos starten →